Antifungal Strategy in Patients with Invasive Fungal Disease Associated with Hematological Malignancies Based on Risk Stratification

Table 2

Patients’ characteristics.

Baseline data		Empirical therapy group	Diagnostic-driven therapy group	value
Sex	Male	143	142	0.27
	Female	96	77
Age		49 (39, 60)	53 (39, 64)	0.10
Neutropenia duration		12.38 ± 10.17	10.35 ± 10.67	0.04
HMs	AML	131	102	0.29
	ALL	33	28
	HAL	1	1
	MDS	13	16
	MM	10	22
	NHL/HD	47	44
	CML	1	2
	CLL	3	4
Disease status	Newly diagnosed	110	100	0.75
	CR	23	20
	Relapsed/refractory	54	43
	PR/SD	52	56
Glucocorticoids for more than 3 weeks	Yes	47	44	0.91
	No	192	175
IFD history	Yes	56	45	0.46
	No	183	174
Diabetes	Yes	22	33	0.07
	No	217	186
Pulmonary dysfunction	Yes	3	6	0.25
	No	236	213